Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Enterprise Value (2018 - 2025)

10x Genomics' Enterprise Value history spans 8 years, with the latest figure at -$523.4 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 33.05% year-over-year to -$523.4 million; the TTM value through Dec 2025 reached -$523.4 million, down 33.05%, while the annual FY2025 figure was -$523.4 million, 33.05% down from the prior year.
  • Enterprise Value for Q4 2025 was -$523.4 million at 10x Genomics, down from -$482.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$222.4 million in Q4 2022 and bottomed at -$640.1 million in Q2 2021.
  • The 5-year median for Enterprise Value is -$395.8 million (2024), against an average of -$425.9 million.
  • The largest annual shift saw Enterprise Value skyrocketed 62.14% in 2022 before it plummeted 74.79% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$587.4 million in 2021, then surged by 62.14% to -$222.4 million in 2022, then tumbled by 74.79% to -$388.7 million in 2023, then dropped by 1.21% to -$393.4 million in 2024, then plummeted by 33.05% to -$523.4 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Enterprise Value are -$523.4 million (Q4 2025), -$482.1 million (Q3 2025), and -$447.3 million (Q2 2025).